Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,732 across all filing types
Latest filing 2022-03-17 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
110年度營益分析
Interim / Quarterly Report Classification · 95% confidence The document contains quarterly and annual financial performance data including revenue, gross margin, operating profit margin, pre-tax profit margin, and after-tax profit margin for multiple fiscal years. The data is structured in a tabular format showing results for first quarter, half-year, third quarter, and full year. The presence of detailed financial metrics for multiple periods within fiscal years indicates this is a comprehensive financial report for periods shorter than a full fiscal year, consistent with an Interim / Quarterly Report. The document length is short (1055 characters), but it contains substantive financial data rather than just an announcement or certification. Therefore, it is classified as an Interim / Quarterly Report (IR). FY 2021
2022-03-17 Chinese
110年第4季權益變動表
Interim / Quarterly Report Classification · 95% confidence The document contains detailed tables of consolidated equity changes for a company, including items such as common stock capital, capital surplus, legal surplus reserve, special surplus reserve, undistributed earnings, retained earnings, foreign currency translation adjustments, and treasury stock. The data is presented for the current period and the previous year, with amounts in thousands of New Taiwan Dollars. This type of detailed financial data on equity changes is typical of a comprehensive financial report rather than a brief announcement or a certification. The document length is 4999 characters, which is sufficient to contain substantive financial data. There is no indication that this is merely an announcement or a certification. The content aligns with what would be found in an Interim / Quarterly Report (IR) or Annual Report (10-K). However, since the data is for a specific period (the 110th year of the Republic of China calendar, corresponding to 2021) and includes detailed equity changes, it is more consistent with an Interim / Quarterly Report rather than a full Annual Report, which would include more comprehensive financial statements and management discussion. Therefore, the best classification is Interim / Quarterly Report (IR). FY 2021
2022-03-17 Chinese
本公司將召開線上法人說明會
Regulatory Filings Classification · 95% confidence The document is a short announcement (722 characters) about the scheduling of an online investor conference call (法人說明會) by the company 美時 (1795). It provides details such as date, time, and access links for the call. There is no actual financial data or report content included, only information about the event. According to the classification rules, announcements about upcoming investor presentations or conference calls fall under Investor Presentation (IP) if they contain the presentation itself, or Regulatory Filings (RNS) if they are just notices. Since this document only announces the event and provides access information without the presentation content, it is best classified as a Regulatory Filing (RNS).
2022-03-16 Chinese
本公司受邀參加統一證券舉辦之2022 Q1春生萬物 全球展望春季投資論壇
Investor Presentation Classification · 90% confidence The document is a short announcement (679 characters) about the company 1795 美時 participating in a securities-hosted investment forum (2022 Q1春生萬物 全球展望春季投資論壇). It mentions the date, time, and location of the investor presentation and states that the company will explain its financial and operational status to institutional investors. There is no detailed financial data or report content included, only an invitation and summary of the event. The document also directs readers to the public information site for full financial and business information. Given the short length and nature of the content, this is an announcement of an investor presentation event rather than the presentation or report itself. Therefore, the appropriate classification is Investor Presentation (IP).
2022-03-16 Chinese
本公司董事會決議辦理限制員工權利新股收回註銷減資事宜
Share Issue/Capital Change Classification · 95% confidence The document is a regulatory announcement from a listed company (1795 美時) regarding a board resolution to cancel and reduce capital due to the recall of restricted employee shares. It includes details such as the date of the board resolution, amount of capital reduction, number of shares canceled, and other related information. There is no indication of a full financial report, audit, or earnings release. The content is about a capital change event (share cancellation and capital reduction). The document length is short (804 characters), and it is a direct announcement of a capital change event, not a report or presentation. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2022-03-16 Chinese
公告本公司董事會通過購買Cialis (Tadalafil)台灣地區產品權利
Capital/Financing Update Classification · 95% confidence The document is a company announcement regarding the board's approval to purchase product rights (Cialis) in Taiwan. It includes details about the transaction such as the date, parties involved, transaction amount, and approval dates. There are no financial statements, quarterly or annual results, or detailed financial analysis. The document is short (1814 characters) and focuses on a specific capital transaction. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2022-03-16 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.